Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Net revenue	$ 724,508	$ 701,780	$ 1,419,928	$ 1,360,971
Cost of goods sold	438,255	451,833	877,784	872,964
Gross profit	286,253	249,947	542,144	488,007
Selling, general and administrative	124,266	116,462	242,554	229,057
Research and development	47,964	36,054	88,004	75,352
Intellectual property legal development expenses	2,017	1,042	3,784	2,026
Restructuring and other charges	1,024	220	1,595	1,690
(Credit) charges related to legal matters, net	(390)	699	(390)	95,058
Other operating (income) expense	0	0	(5,122)	100
Operating income (loss)	111,372	95,470	211,719	84,724
Other (expense) income:
Interest expense, net	(65,101)	(65,719)	(122,040)	(131,422)
Foreign exchange gain (loss), net	8,256	(262)	12,503	(1,459)
Increase in tax receivable agreement liability	(4,420)	(13,444)	(15,107)	(15,392)
Other income, net	1,604	4,360	2,122	8,432
Total other expense, net	(59,661)	(75,065)	(122,522)	(139,841)
Income (loss) before income taxes	51,711	20,405	89,197	(55,117)
Provision for income taxes	16,101	3,618	28,969	9,774
Net income (loss)	35,610	16,787	60,228	(64,891)
Less: Net income attributable to non-controlling interests	(13,193)	(10,793)	(25,616)	(20,758)
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.	$ 22,417	$ 5,994	$ 34,612	$ (85,649)
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic (in dollars per share)	$ 0.07	$ 0.02	$ 0.11	$ (0.28)
Diluted (in dollars per share)	$ 0.07	$ 0.02	$ 0.11	$ (0.28)
Weighted-average common shares outstanding:
Basic (in shares)	313,739	309,117	312,404	308,198
Diluted (in shares)	322,363	318,957	323,171	308,198